糖尿病及治疗期间高血糖对弥漫大B细胞淋巴瘤预后的影响
回顾性分析481例初诊DLBCL患者,评估合并糖尿病及治疗中血糖升高对预后的影响。结果显示合并DM及治疗中血糖升高均与较差的OS和PFS相关,血糖控制良好者预后更优。
要点
- 合并糖尿病是影响DLBCL患者OS和PFS的不良预后因素。
- 治疗过程中血糖升高与DLBCL患者不良预后相关。
- 化疗期间血糖控制良好者OS和PFS优于控制差者。
核心结论
- 合并糖尿病是影响DLBCL患者预后的重要因素。
- 治疗过程中血糖升高与DLBCL患者的不良预后相关。
- 化疗期间血糖控制良好者预后优于血糖控制差者。
研究设计与样本
- 回顾性收集2009年1月1日至2019年12月31日天津医科大学肿瘤医院及中山大学肿瘤防治中心481例初诊DLBCL患者临床资料。
- 重点关注治疗前及治疗中的血糖水平,采用Cox回归风险模型进行单因素分析,Kaplan-Meier法绘制生存曲线。
主要发现
- 82例(17.0%)患者在诊断DLBCL前患DM,88例(18.3%)患者在DLBCL治疗过程中至少发生一次血糖升高。
- 单因素分析显示年龄、Ann-Arbor分期、IPI评分、是否合并DM与OS、PFS相关(P值均<0.05)。
- 合并DM组与治疗过程中血糖升高组的OS和PFS均较无血糖异常组差(OS:P值分别为0.001、0.003,PFS:P值均<0.001)。
- 合并DM组与治疗过程中血糖升高组相比OS和PFS差异均无统计学意义(P值分别为0.557、0.463)。
- 化疗期间血糖控制良好组的OS和PFS优于血糖控制差组(OS:P=0.037,PFS:P=0.007)。
临床怎么用
- 对DLBCL患者应关注治疗前糖尿病状态及治疗期间血糖水平。
- 化疗期间良好控制血糖可能改善DLBCL患者预后。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: This study aims to investigate the clinical features and prognostic factors of patients with diffuse large B-cell lymphoma (DLBCL) and assess the prognostic value of diabetes mellitus (DM) and hyperglycemia during DLBCL treatment in DLBCL. Methods: The clinical data of 481 newly diagnosed DLBCL patients from January 1, 2009 to December 31, 2019 at Tianjin Medical University Cancer Institute and Hospital and Sun Yat-sen University Cancer Center were retrospectively collected, focusing on their blood glucose levels before and during treatment. Cox regression method was used for univariate analysis to assess prognostic factors, and the Kaplan-Meier method was used to draw survival curves to assess the prognostic value of DM and hyperglycemia during DLBCL treatment in patients with DLBCL. Results: Eighty-two (17.0%) patients had DM before DLBCL diagnosis and treatment, and 88 (18.3%) patients had at least one blood glucose increase during DLBCL treatment. Cox univariate analysis showed that age, Ann Arbor stage, international prognostic index, and DM were associated with overall survival (OS) and progression-free survival (PFS) (all P<0.05) . The pairwise comparison between the two groups showed that the OS (P=0.001) and PFS (P<0.001) of patients with pre-existing DM were significantly worse than those of patients without abnormal blood glucose. Moreover, the OS (P=0.003) and PFS (P<0.001) of patients with hyperglycemia during DLBCL treatment were significantly worse than those of patients without abnormal blood glucose. No significant difference exists between patients with DM and patients with hyperglycemia during DLBCL treatment (OS, P=0.557; PFS, P=0.463) . Additionally, patients with adequate glycemic control during chemotherapy had a better prognosis compared with patients with poor glycemic control (OS, P=0.037; PFS, P=0.007) . Conclusion: DM is an important factor affecting the prognosis of patients with DLBCL. Moreover, hyperglycemia during treatment is related to the poor prognosis of patients with DLBCL. 目的: 探讨弥漫大B细胞淋巴瘤(DLBCL)患者的临床特征和预后因素,评估合并糖尿病(DM)及治疗过程中发生血糖升高对DLBCL预后的影响。 方法: 回顾性收集2009年1月1日至2019年12月31日天津医科大学肿瘤医院及中山大学肿瘤防治中心收治的481例初诊DLBCL患者的临床资料,重点关注其治疗前及治疗中的血糖水平,采用Cox回归风险模型进行单因素分析评估预后影响因素,采用Kaplan-Meier法绘制生存曲线分析血糖异常对DLBCL患者总生存(OS)、无进展生存(PFS)的影响。 结果: 82例(17.0%)患者在诊断DLBCL前患DM,88例(18.3%)患者在DLBCL治疗过程中至少发生一次血糖升高。单因素分析显示,年龄、Ann-Arbor分期、IPI评分、是否合并DM与OS、PFS相关(P值均<0.05)。组间比较显示,合并DM组与治疗过程中血糖升高组的OS和PFS均较无血糖异常组差(OS:P值分别为0.001、0.003,PFS:P值均<0.001),合并DM组与治疗过程中血糖升高组相比OS和PFS的差异均无统计学意义(P值分别为0.557、0.463)。化疗期间血糖控制良好组的OS和PFS优于血糖控制差组(OS:P=0.037,PFS:P=0.007)。 结论: 合并DM是影响DLBCL患者预后的重要因素,治疗过程中血糖升高与DLBCL患者的不良预后相关。.
引用
- Hu Y, Xu YJ, Li MZ, et al. [The prognostic impact of diabetic mellitus and hyperglycemia during DLBCL treatment on patients with diffuse large B-cell lymphoma]. Zhonghua Xue Ye Xue Za Zhi. 2021. PMID: 33858047. doi:10.3760/cma.j.issn.0253-2727.2021.02.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。